Across TCGA pan-cancer cohorts, UBALD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UBALD2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher UBALD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated UBALD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, GBM, and LSCC are the cancer types where UBALD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	1.000	0.534	.020	5	view →
GBM	DFS	Median	All	0.560	0.791	.027	4	view →
LSCC	DFS	Quartile	II,III,IV	0.829	0.467	.023	3	view →
UCEC	DFS	Median	All	1.000	0.906	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: UBALD2 tumor-vs-normal RNA expression · all UBALD2 data types